LEO Pharma Open Innovation

Data sharing and way forward

Generated data

All the data generated by testing your compounds in LEO Pharma's disease-relevant in vitro bioassay will be reported to you in full. LEO Pharma will only use the generated data to evaluate if a continued collaboration is of interest. You may use the data generated in any way, including for scientific publication. If so, we ask that you to refer to LEO Pharma Open Innovation and also that we are notified about such publication.

Possible way forward

If the results indicate an interesting possibility we will suggest a follow-up profiling, which could include studies to address e.g.:

  • Additional in vitro assays profiling
  • Cytotoxicity
  • Drug Metabolism and Pharmacokinetic evaluation
  • Compound physical and chemical properties
  • Testing for in vivo effect

The details of the follow-up profiling will be handled on a case-by-case basis. There are many factors that affect the decision to progress a project further, e.g.:

  • The effect in some assays and not in others
  • Effect on viability
  • Pharmacological profile
  • Previously related projects
  • Technological match
  • Current patient need focus

Expectations and experience

What we all hope for is to detect that your compound has a specific, efficacious and potent bioactivity, combined with favorable physical-chemical properties and intellectual ownership situation.

In our experience this happens only rarely and we would like to emphasize that it is more likely that the result will not be favorable.

Drug discovery often relies on serendipity or simply numerous iterations – but, of course, there is always a chance that the first step towards the next innovative patient treatment is actually discovered using the disease-relevant in vitro assays as provided by LEO Pharma Open Innovation.

If the promising compound does not work

Please do note that lack of biological effect in the Open Innovation assays doesn’t necessarily mean that the compound is concluded to be without value.

It might simply be that it doesn’t fit in the current disease and technology platform, or that the compound targets a pathway that is not present in the simplified disease-relevant in vitro assay.

Case-by-case evaluation and discussion under CDA

Should data look promising, we will return with a suggestion to sign a Confidentiality Disclosure Agreement (CDA) in order to continue with a more detailed follow-up discussion to assess how working together could be of benefit to you, to us and most importantly to patients.